Mon, Jul 28, 2014, 11:58 AM EDT - U.S. Markets close in 4 hrs 2 mins


% | $
Click the to save as a favorite.

Boston Scientific Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • dexter_egghead dexter_egghead Nov 10, 2005 3:26 PM Flag


    All the massive lawsuits and class actions are not factored in. This CO. is about to lose billions and when the FDA shuts down 40% of their revenue this stock will drop fast. Never mind all the new companies about to enter the market and steal BSX lunch. There is going to be serious problems ahead, it can and will get worse. Their products are the worst on the market and have actually resulted in numerous deaths and injury. The insiders are bailing. The FDA is about to shut them down. Its getting downgraded and it hasn't even missed earnings yet. The competition is about to take over their territory, and the massive debt is strangleing, when the lawsuits kick in there is going to be no money to pay for debt and new products. When the fundamentals start evaporating people will run for the exits and wake up to the fact this is a $12 stock

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Why pump this turkey? If you want to own poop buy in at $15. Who wants to buy the insiders shares they are dumping.
      Boston Scientific Reports $269M Loss in 3Q
      Friday October 14, 5:17 pm ET
      By Mark Jewell, AP Business Writer
      Boston Scientific Reports $269 Million 3Q Loss , Dip in Coronary Stent Sales

      BOSTON (AP) -- Boston Scientific Corp. on Friday acknowledged it has lost ground to medical device rivals in the lucrative market for drug-coated heart stents, reporting a $269 million third-quarter loss and slowing sales of a stent.

      The performance, fell short of Boston Scientific's projection and Wall Street's expectations.

      "We still think that management might be too optimistic and that earnings estimates still need to be lowered."

      Morgan Stanley said the challenge for Boston Scientific in the coming quarters will be holding off market share losses as Johnson & Johnson (nyse: JNJ - news - people )expands capacity and Medtronic (nyse: MDT - news - people ) introduces Endeavor in Europe.

      "As we look to future, we still see some downside relative to stent market share, market size and estimated margins. We should also point out that there is little in place (with respect to the pipeline)

      U.S. govt warns against Boston Scientific device
      Tue Oct 18, 2005 12:10 AM ET
      NEW YORK, Oct 17 (Reuters) - The U.S. Food and Drug Administration told doctors on Monday to stop using Enteryx, a device used to treat acid-reflux disease that Boston Scientific Corp. (BSX.N: Quote, Profile, Research) recalled last month.
      The FDA said doctors should immediately stop injecting Enteryx, due to serious adverse effects, including death, occurring in patients treated with the liquid chemical polymer used for gastroesophageal reflux disease.

      Enteryx is intended to be injected into the lower esophageal sphincter where it polymerizes into a spongy material that cannot be removed, the FDA said in a notice on its Web site (

      Boston Scientific issued a recall of its Enteryx procedure kits and its Enteryx injector single packs on Sept. 23, the FDA said.

      • 3 Replies to shirlylong42
      • Pathetic bunch of demented liars, will say anything to try to eke out a few lousy pennies of blood money.

        GET A JOB

        GET A LIFE

      • Shirly,

        Do you know how much profit they earned in Q3 but for the important settlment with Medinol? Wasn't is it something like 400 million?

        How much money will the earn this quarter? Do you really expect them to post another "loss"? Or do you expect to see, in the absense of the one-time Medinol payment, another great quarter in the 400 million profit range?

        Given these facts, using the same logic and spirit of your post, would it be fair for me to say "Boston Scientifc posts quarter over quarter increase in profit of $800 million in Q4" when this happens?

        Don't you want to invest in a company that increased it profits nearly a billion dollars in a single quarter?

      • I don't like some of the things I've found out about the company, I am selling also, I have been very disapointed by the stock all year, I will be happy to join the class action lawsuit too, looks like thats the only way to make any money with this dud of a stock, these insiders are just dumping stock and wasting shareholder equity, why do they get paid so much to do nothing? We have decreasing cash every quarter this year, and now losses? Why don't they do something about the debt? This is rediculous, oh well I'm done with it I'm getting out. Good luck girl.

    • You know, like dexter_egghead and his/her/its many aliases.

      Continuous stream of lying bullsh*t, no matter what is reported to prove them all liers...

    • Heres the real news.
      The Pomerantz Firm Charges Boston Scientific Corporation with Securities Fraud -- BSX
      Thursday November 3, 11:40 am ET
      NEW YORK, Nov. 3, 2005 (PRIMEZONE) -- Pomerantz Haudek Block Grossman & Gross LLP ( filed a class action lawsuit on November 2, 2005, on behalf of purchasers of securities of Boston Scientific Corporation (``Boston Scientific'' or the ``Company'') (NYSE:BSX - News) during the period from March 31, 2003 through August 23, 2005, inclusive (the ``Class Period''). The Complaint charges that Defendants violated the Securities Exchange Act of 1934 (Sections 10(b) and 20(a) and Rule 10b-5 promulgated thereunder) by making false and misleading statements to the investing public as to the Company's ability to satisfy FDA regulations governing its medical device product quality, as well as affirmative representations as to the Company's knowlege and expertise regarding design, development, marketing approval and sales of its medical devices.
      The true facts, which were known to each of the defendants but concealed from the investing public, were that (i) the Company's internal controls, corporate compliance processes and systems as they were directly related to the medical device product life cycle were deficient and defective; (ii) the Company suffered from longstanding, basic, chronic and global deficiencies in its quality practices; (iii) the Company had failed to comply with numerous FDA medical device regulations and federal statutes governing its quality practices; and (iv) public safety was at risk, since the Company was unable to reliably assure safety and efficacy for any of its products.
      On August 23, 2005, based on the cumulative impact of three separate FDA Warning Letters, investors finally learned of the true nature of defendants' concealment of its broken quality program and the risks the Company faced that were completely unrelated to the Company's ongoing and unpredictable patent litigation agenda. The truth was that the performance of the Company was immediately related to the revelations of quality and regulatory obstacles impacting marketability. If you purchased Boston Scientific Corporation securities during the Class Period, you have until November 21, 2005 to ask the Court to appoint you as lead plaintiff for the Class. Lead plaintiffs must meet certain legal requirements. Shareholders outside the United States may also join the action, regardless of where they live or which exchange was used to purchase the securities. If you wish to review a copy of the Complaint, to discuss this action, or have any questions, please contact Teresa L. Webb ( or Carolyn Moskowitz ( via email or call the Pomerantz Firm at (888) 476-6529 (888 4-POMLAW), toll free. Those who inquire by e-mail are encouraged to include their mailing address and phone number.
      The Pomerantz Firm, which has offices in New York, Chicago and Washington, D.C., is acknowledged as one of the premier firms in the areas of corporate, securities and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 50 years later, the Pomerantz Firm continues in the tradition Mr. Pomerantz established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty and corporate misconduct. The firm has recovered numerous multimillion-dollar damages awards on behalf of class members. For more information about the firm, visit our web site at

12.935-0.175(-1.33%)11:57 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.